- Home
- ARDX
ARDX
Ardelyx Inc.
as of 03-19-2026 3:56pm EST
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
| Founded: | 2007 | Country: | United States |
| Employees: | N/A | City: | FREMONT |
| Market Cap: | 1.6B | IPO Year: | 2014 |
| Target Price: | $15.14 | AVG Volume (30 days): | 3.5M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.26 | EPS Growth: | -52.94 |
| 52 Week Low/High: | $3.50 - $8.40 | Next Earning Date: | 04-30-2026 |
| Revenue: | $2,607,000 | Revenue Growth: | -93.79% |
| Revenue Growth (this year): | 38.22% | Revenue Growth (next year): | 33.85% |
| P/E Ratio: | -21.35 | Index: | N/A |
| Free Cash Flow: | -43975000.0 | FCF Growth: | N/A |
AI-Powered ARDX Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Ardelyx Inc. (ARDX)
President & CEO
Avg Cost/Share
$5.84
Shares
41,666
Total Value
$243,329.44
Owned After
1,816,448
SEC Form 4
President & CEO
Avg Cost/Share
$6.26
Shares
41,666
Total Value
$260,620.83
Owned After
1,816,448
SEC Form 4
Director
Avg Cost/Share
$5.84
Shares
333,333
Total Value
$1,946,331.39
Owned After
3,302,918
SEC Form 4
President & CEO
Avg Cost/Share
$5.74
Shares
45,982
Total Value
$268,840.52
Owned After
1,816,448
See Remarks
Avg Cost/Share
$5.79
Shares
8,176
Total Value
$47,803.46
Owned After
436,082
See Remarks
Avg Cost/Share
$5.76
Shares
3,179
Total Value
$18,586.31
Owned After
339,152
See Remarks
Avg Cost/Share
$5.76
Shares
9,595
Total Value
$56,099.11
Owned After
364,666
Chief Commercial Officer
Avg Cost/Share
$5.75
Shares
10,439
Total Value
$61,033.75
Owned After
425,972
See Remarks
Avg Cost/Share
$5.76
Shares
4,991
Total Value
$29,180.86
Owned After
151,792
Chief Financial Officer
Avg Cost/Share
$5.79
Shares
2,033
Total Value
$11,886.20
Owned After
230,533
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| RAAB MICHAEL | ARDX | President & CEO | Mar 16, 2026 | Sell | $5.84 | 41,666 | $243,329.44 | 1,816,448 | |
| RAAB MICHAEL | ARDX | President & CEO | Feb 24, 2026 | Sell | $6.26 | 41,666 | $260,620.83 | 1,816,448 | |
| MOTT DAVID M | ARDX | Director | Feb 20, 2026 | Buy | $5.84 | 333,333 | $1,946,331.39 | 3,302,918 | |
| RAAB MICHAEL | ARDX | President & CEO | Feb 20, 2026 | Sell | $5.74 | 45,982 | $268,840.52 | 1,816,448 | |
| Williams Laura A | ARDX | See Remarks | Feb 20, 2026 | Sell | $5.79 | 8,176 | $47,803.46 | 436,082 | |
| Bishop John E | ARDX | See Remarks | Feb 20, 2026 | Sell | $5.76 | 3,179 | $18,586.31 | 339,152 | |
| Kelliher Mike | ARDX | See Remarks | Feb 20, 2026 | Sell | $5.76 | 9,595 | $56,099.11 | 364,666 | |
| Foster Eric Duane | ARDX | Chief Commercial Officer | Feb 20, 2026 | Sell | $5.75 | 10,439 | $61,033.75 | 425,972 | |
| Reilly Joseph James | ARDX | See Remarks | Feb 20, 2026 | Sell | $5.76 | 4,991 | $29,180.86 | 151,792 | |
| Hohenleitner Susan | ARDX | Chief Financial Officer | Feb 20, 2026 | Sell | $5.79 | 2,033 | $11,886.20 | 230,533 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q4 Q4 2025 Earnings
8-K BUY Feb 19, 2026 · 100% conf.
Q4 2025 Earnings
8-K BUYFeb 19, 2026 · 100% conf.
1D
+11.69%
$7.55
Act: -15.24%
5D
+11.39%
$7.53
Act: -1.92%
20D
+10.50%
$7.47
ardx-202602190001437402false00014374022026-02-192026-02-19
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 19, 2026
ARDELYX, INC.
(Exact name of registrant as specified in its charter)
Delaware001-3648526-1303944 (State or other jurisdiction of incorporation)(Commission File Number)(IRS Employer Identification Number)
400 FIFTH AVE., SUITE 210, WALTHAM, MASSACHUSETTS 02451
(Address of principal executive offices, including Zip Code) Registrant’s telephone number, including area code: (510) 745-1700
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, par value $0.0001 per shareARDXThe Nasdaq Global Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 2.02 Results of Operations and Financial Condition. On February 19, 2026, Ardelyx, Inc. (the “Company”) announced its financial results for the quarter and year ended December 31, 2025. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information furnished under this Item 2.02, including Exhibit 99.1 hereto, shall not be considered “filed” under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall it be incorporated by reference into any future filing under the Securities Act of 1933, as amended (the “Securities Act”), or under the Exchange Act, unless the Company expressly sets forth in such future filing that such information is to be considered “filed” or incorporated by reference therein.
Item 7.01 Regulation FD Disclosure.
On February 19, 2026, the Company will host a conference call to discuss its financial results for the quarter and year ended December 31, 2025. A copy of the earnings presentation that will be used during this conference call is furnished as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference. The information furnished under this Item 7.01, including Exhibit 99.2 hereto, shall not be considered “filed” under the Exchange Act nor shall it be incorporated by reference into any future filing under the Securities Act, or under the Exchange Act, unless the Company expressly sets forth in such future filing that such information is to be considered “filed” or incorporated by reference therein.
Item 9.01 Financial Statements and Exhibits. (d) Exhibits.
Exhibit No. Description 99.1Press Release of Ardelyx, Inc.
99.2Earnings Presentation of Ardelyx, Inc.
104Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: February 19, 2026ARDELYX, INC.
By:/s/ Susan Hohenleitner Susan Hohenleitner Chief Financial Officer
2025 Q4 Q4 2025 Earnings
8-K BUY Jan 8, 2026 · 100% conf.
Q4 2025 Earnings
8-K BUYJan 8, 2026 · 100% conf.
1D
+11.69%
$7.55
Act: -15.24%
5D
+11.39%
$7.53
Act: -1.92%
20D
+10.50%
$7.47
ardx-202601080001437402false00014374022026-01-082026-01-08
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2026
ARDELYX, INC.
(Exact name of registrant as specified in its charter)
Delaware001-3648526-1303944 (State or other jurisdiction of incorporation)(Commission File Number)(IRS Employer Identification Number)
400 FIFTH AVE., SUITE 210, WALTHAM, MASSACHUSETTS 02451
(Address of principal executive offices, including Zip Code) Registrant’s telephone number, including area code: (510) 745-1700
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, par value $0.0001 per shareARDXThe Nasdaq Global Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 2.02 Results of Operations and Financial Condition.
On January 8, 2026, Ardelyx, Inc. (the “Company”) announced:
•Unaudited U.S. net product sales revenue of IBSRELA® (tenapanor) of approximately $87 million for the fourth quarter ended December 31, 2025, and approximately $274 million for the full year ended December 31, 2025. •Unaudited U.S. net product sales revenue of XPHOZAH® (tenapanor) of approximately $28 million for the fourth quarter ended December 31, 2025, and approximately $104 million for the full year ended December 31, 2025.
The Company also announced that as of December 31, 2025, it had cash, cash equivalents, and short-term investments of approximately $265 million, unaudited.
These amounts are preliminary and are subject to adjustment in connection with preparation of audited financial statements. As a result, these amounts may differ materially from the amounts that will be reflected in the Company’s financial statements for the year ended December 31, 2025.
The preliminary financial data included in this Current Report on Form 8-K has been prepared by, and is the responsibility of, the Company’s management. Ernst & Young LLP has not audited, reviewed, examined, compiled, nor applied agreed-upon procedures with respect to the preliminary financial data. Accordingly, Ernst & Young LLP does not express an opinion or any other form of assurance with respect thereto.
Item 8.01 Other Events. The information set forth in Item 2.02 is incorporated into this Item 8.01 by reference.
Item 9.01 Financial Statements and Exhibits. (d) Exhibits.
Exhibit No.Description 104Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: January 8, 2026ARDELYX, INC.
By:/s/ Susan Hohenleitner Susan Hohenleitner Chief Financial Officer
2025 Q3 Q3 2025 Earnings
8-K Oct 30, 2025
Q3 2025 Earnings
8-KOct 30, 2025
ardx-202510300001437402false00014374022025-10-302025-10-30
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 30, 2025
ARDELYX, INC.
(Exact name of registrant as specified in its charter)
Delaware001-3648526-1303944 (State or other jurisdiction of incorporation)(Commission File Number)(IRS Employer Identification Number)
400 FIFTH AVE., SUITE 210, WALTHAM, MASSACHUSETTS 02451
(Address of principal executive offices, including Zip Code) Registrant’s telephone number, including area code: (510) 745-1700
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, par value $0.0001ARDXThe Nasdaq Global Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 2.02 Results of Operations and Financial Condition. On October 30, 2025, Ardelyx, Inc. (the “Company”) announced its financial results for the quarter ended September 30, 2025. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information furnished under this Item 2.02 shall not be considered “filed” under the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference into any future filing under the Securities Act of 1933, as amended, or under the Securities Exchange Act of 1934, as amended, unless the Company expressly sets forth in such future filing that such information is to be considered “filed” or incorporated by reference therein.
Item 9.01 Financial Statements and Exhibits. (d) Exhibits.
Exhibit No. Description 99.1Press release of Ardelyx, Inc.
104Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: October 30, 2025ARDELYX, INC.
By:/s/ Justin Renz Justin Renz Chief Financial and Operations Officer
Compare ARDX vs Leading Stocks
See how ARDX stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "ARDX Ardelyx Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.